Published March 2019 | Version v1
Journal article Metadata-only

Daily Lisinopril vs Placebo for Prevention of Chemoradiation-Induced Pulmonary Distress in Patients With Lung Cancer (Alliance MC1221): A Pilot Double-Blind Randomized Trial

Creators

  • 1. Department of Radiation Oncology, Mayo Clinic Hospital, Phoenix (United States)
  • 2. Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester (United States)
  • 3. Department of Radiation Oncology, University of Nebraska Medical Center, Omaha (United States)
  • 4. Department of Radiation Oncology, Mayo Clinic, Rochester (United States)

Description

Chemoradiation (CRT) is an integral treatment modality for patients with locally advanced lung cancer. It has been hypothesized that current use of an angiotensin-converting enzyme inhibitor during CRT may be protective for treatment-related lung damage and pneumonitis.

Additional details

Identifiers

DOI
10.1016/j.ijrobp.2018.10.035;
PII
S0360301618339245;

Publishing Information

Journal Title
International Journal of Radiation Oncology, Biology and Physics
Journal Volume
103
Journal Issue
3
Journal Page Range
p. 686-696
ISSN
0360-3016
CODEN
IOBPD3

INIS

Country of Publication
United States
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
55060907
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
ANGIOTENSIN; ENZYME INHIBITORS; LUNGS; NEOPLASMS; PATIENTS; PNEUMONITIS
Descriptors DEC
BODY; CARDIOVASCULAR AGENTS; DISEASES; DRUGS; GLOBULINS; ORGANIC COMPOUNDS; ORGANS; PROTEINS; RESPIRATORY SYSTEM; VASOCONSTRICTORS

Optional Information

Copyright
Copyright (c) 2018 Published by Elsevier Inc.